[{"id":"a02a2c56-66cc-4055-a740-920b93e5d580","acronym":"","url":"https://clinicaltrials.gov/study/NCT02872025","created_at":"2021-01-18T14:06:02.683Z","updated_at":"2025-02-25T16:05:06.842Z","phase":"Phase 1","brief_title":"Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)","source_id_and_acronym":"NCT02872025","lead_sponsor":"Laura Esserman","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mRNA-2752"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/12/2016","start_date":" 12/12/2016","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-01-30"},{"id":"05863608-f300-43a5-8fe7-d4a2003c3fae","acronym":"mRNA-2752-P101","url":"https://clinicaltrials.gov/study/NCT03739931","created_at":"2021-10-27T19:53:08.482Z","updated_at":"2025-02-25T15:08:05.703Z","phase":"Phase 1","brief_title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","source_id_and_acronym":"NCT03739931 - mRNA-2752-P101","lead_sponsor":"ModernaTX, Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" PD-L1 negative • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • mRNA-2752"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 03/10/2026","primary_completion_date":" 03/10/2026","study_txt":" Completion: 03/10/2026","study_completion_date":" 03/10/2026","last_update_posted":"2024-05-17"}]